AR044800A1 - Sales de potasio y/o sodio del acido (-)-2-{[2-(4-hidroxifenil)etil]tio}-3-[4-(2-{4-[(metilsulfonil)oxi]fenoxi}etil)fenil] propanoico - Google Patents

Sales de potasio y/o sodio del acido (-)-2-{[2-(4-hidroxifenil)etil]tio}-3-[4-(2-{4-[(metilsulfonil)oxi]fenoxi}etil)fenil] propanoico

Info

Publication number
AR044800A1
AR044800A1 ARP040102110A ARP040102110A AR044800A1 AR 044800 A1 AR044800 A1 AR 044800A1 AR P040102110 A ARP040102110 A AR P040102110A AR P040102110 A ARP040102110 A AR P040102110A AR 044800 A1 AR044800 A1 AR 044800A1
Authority
AR
Argentina
Prior art keywords
ethyl
propanoic
hydroxyphenyl
phenoxy
phenyl
Prior art date
Application number
ARP040102110A
Other languages
English (en)
Inventor
Matti Ahiqvist
Martin Hans Bohlin
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR044800A1 publication Critical patent/AR044800A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/56—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table
    • C07F1/06—Potassium compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table
    • C07F1/04—Sodium compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Una sal de potasio o una sal de sodio de ácido (-)-2{[2-(4-hidroxifenil)etil]tio}3-3[4-(2-{4-[(metilsulfonil)oxi]fenoxi}etil)fenil]propanoico, procesos para su preparación, su uso en el tratamiento de afecciones clínicas incluyendo trastornos en los lípidos (dislipidemias) asociadas o no a la resistencia a la insulina y otras manifestaciones del síndrome metabólico, y composiciones farmacéuticas que los contienen.
ARP040102110A 2003-06-18 2004-06-17 Sales de potasio y/o sodio del acido (-)-2-{[2-(4-hidroxifenil)etil]tio}-3-[4-(2-{4-[(metilsulfonil)oxi]fenoxi}etil)fenil] propanoico AR044800A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0314131.4A GB0314131D0 (en) 2003-06-18 2003-06-18 Therapeutic agents

Publications (1)

Publication Number Publication Date
AR044800A1 true AR044800A1 (es) 2005-10-05

Family

ID=27636790

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040102110A AR044800A1 (es) 2003-06-18 2004-06-17 Sales de potasio y/o sodio del acido (-)-2-{[2-(4-hidroxifenil)etil]tio}-3-[4-(2-{4-[(metilsulfonil)oxi]fenoxi}etil)fenil] propanoico

Country Status (20)

Country Link
US (1) US20070099997A1 (es)
EP (1) EP1641749A1 (es)
JP (1) JP2006527750A (es)
KR (1) KR20060026427A (es)
CN (1) CN1835920A (es)
AR (1) AR044800A1 (es)
AU (1) AU2004249485A1 (es)
BR (1) BRPI0411515A (es)
CA (1) CA2529251A1 (es)
CO (1) CO5650240A2 (es)
GB (1) GB0314131D0 (es)
IL (1) IL172440A0 (es)
IS (1) IS8234A (es)
MX (1) MXPA05013826A (es)
NO (1) NO20055927L (es)
RU (1) RU2005141068A (es)
TW (1) TW200503679A (es)
UY (1) UY28367A1 (es)
WO (1) WO2004113284A1 (es)
ZA (1) ZA200510196B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0104333D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
EP1517883B8 (en) 2002-06-20 2008-05-21 AstraZeneca AB Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance
GB0314075D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0427524D0 (en) 2004-12-16 2005-01-19 Astrazeneca Ab Chemical process

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089514A (en) * 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
US5232945A (en) * 1992-07-20 1993-08-03 Pfizer Inc. 3-aryl-2-hydroxypropionic acid derivatives and analogs as antihypertensives
MA26634A1 (fr) * 1998-06-04 2004-12-20 Astra Ab Nouveaux derives de l'acide 3-aryl propionique et analogues
SE9801992D0 (sv) * 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
TWI262185B (en) * 1999-10-01 2006-09-21 Eisai Co Ltd Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives
SE0000772D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab Chemical compounds
TWI311133B (en) * 2001-04-20 2009-06-21 Eisai R&D Man Co Ltd Carboxylic acid derivativeand the salt thereof
GB0121621D0 (en) * 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
PL216023B1 (pl) * 2001-09-08 2014-02-28 Astrazeneca Ab Pochodna benzotiadiazepiny, kompozycja farmaceutyczna zawierajaca pochodna benzotiadiazepiny oraz zastosowania pochodnej benzotiadiazepiny
SE0104333D0 (sv) * 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
GB0314130D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314075D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents

Also Published As

Publication number Publication date
GB0314131D0 (en) 2003-07-23
BRPI0411515A (pt) 2006-08-01
US20070099997A1 (en) 2007-05-03
RU2005141068A (ru) 2007-07-27
MXPA05013826A (es) 2006-02-28
UY28367A1 (es) 2005-01-31
CN1835920A (zh) 2006-09-20
IL172440A0 (en) 2006-04-10
TW200503679A (en) 2005-02-01
KR20060026427A (ko) 2006-03-23
WO2004113284A1 (en) 2004-12-29
ZA200510196B (en) 2006-12-27
JP2006527750A (ja) 2006-12-07
EP1641749A1 (en) 2006-04-05
CA2529251A1 (en) 2004-12-29
AU2004249485A1 (en) 2004-12-29
NO20055927L (no) 2006-01-27
CO5650240A2 (es) 2006-06-30
IS8234A (is) 2006-01-16

Similar Documents

Publication Publication Date Title
AR068323A1 (es) Compuestos del acido 2-{2-cloro-5-{[(2s)-3-(5-cloro-1'-h,3h-espiro[1-benzofuran-2,4'-piperidin]-1' -il)-2-hidroxipropil]oxi}4-[(metilamino)carbonil]fenoxi}-2-metilpropanoico, composiciones farmaceuticas que los contienen, metodo de preparacion y usos de los mismos en afecciones respiratorias
CL2007001873A1 (es) Acido((3s))-6-((¨2,6-dimetil-4-(3-(metilsulfonil)-propoxi)bifenil-3-il)metoxi-2,3-dihidro-1-benzofuran-3-il)acetico o una sal del mismo
HRP20211281T1 (hr) Pripravci koji sadrže inzulin
CY1109307T1 (el) Χρηση αδαπαλενιου για τη θεραπεια δερματολογικων διαταραχων
CL2011002941A1 (es) Sales de disacarina, acido difumarico, acido di-1-hidroxi-2-naftoico y acido monobenzoico de 2-(4-((2-amino-4-metil-6-(pentilamino)pirimidin-5-il)metil)fenil)acetato de 4-(dimetilamino)butilo; composicion farmaceutica; y uso en el tratamiento de asma, epoc, cancer, vih, hepatitis b y c, infecciones bacterianas.
JP2015514120A5 (es)
ATE394094T1 (de) Tablette enthaltend 3-((2-ä(4- (hexyloxycarbonylamino-imino-methyl)-phenylamin )-methylü-1-methyl-1h-benzimidazol-5-carbonyl)- pyridin-2-yl-amino)-propionsäure-ethylester oder dessen salze
ECSP099056A (es) Azolilmetiloxiranos, su uso para combatir hongos fitopatógenos, así como productos que los contienen
CL2024000756A1 (es) Sal de potasio de ácido 2-[4-[(5,6-difenilpirazin-2-il)-propan-2-ilamino]butoxi]acético
HRP20190589T1 (hr) Antimalarijski spojevi sa fleksibilnim bočnim-lancima
PE20091213A1 (es) Formas solidas de acido (s)-2-amino-3-(4-(2-amino-6-((r)-2,2,2-trifluoro-1-(3'-metoxibifenil-4-il)etoxi)pirimidin-4-il)fenil)propanoico
AR044826A1 (es) Sales derivadas del acido propionico,y su uso medicinal
PE20081200A1 (es) Sal de potasio cristalina de analogos de lipoxina a4
BRPI0407758A (pt) derivados de 3-(2-fenil-oxazol-4-ilmetóxi)-ciclohexilmetóxi-acético e compostos afins como modula-dores de ppar para o tratamento de diabetes do tipo 2 e aterosclerose.
UY28367A1 (es) Agentes terapéuticos
CO5590908A2 (es) Derivados de acido 3-fenil-2-arilalquiltiopropionico como antagonistas selectivos de ppar-alfa
AR051998A1 (es) Agentes terapeuticos
AR058109A1 (es) Acido 3 - (4 - {[4 -(4 -{[3 - (3, 3 - dimetil - 1 - piperidinil)propil]oxi}fenil) - 1 - piperidinil]carbonil} - 1 - naftalenil)propanoico como antagonistas de los receptotres de histamina h1/h3, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamie
AR053155A1 (es) Derivados de 1, 2, 4 - triazinas, su preparacion, composiciones farmaceuticas que los contienen y su aplicacion en el tratamiento de enfermedades mediadas por la activacion de los receptores ppar gamma y/o alfa.
UY29272A1 (es) Agentes terapeuticos
BR112015017708A2 (pt) solução aquosa estável
AR090619A2 (es) Uso de un compuesto de tiazol para la produccion de un medicamento
NO20055883L (no) Fremgangsmate for fremstilling av racemisk 2-{[2-(4-hydroksfenyl)etyl]tio}-3-[4-(2-{4-[(metylsulfonyl)oksy]fenoksy}etyl)fenyl]-propansyre
HK1087396A (en) Potassium or sodium salt of (-)-2- {'2-(4-hydroxyphenyl)ethyl]-thio -3-'4-(2- {4-'(methylsulfonyl)oxy ]phenoxy }phenyl]propanoic acid and their use in medicine.
SE0101981D0 (sv) Pharmaceutical combination

Legal Events

Date Code Title Description
FA Abandonment or withdrawal